狼疮肾炎肾功能丢失的临床、组织学与血清学预测因素
本研究在加速药物伙伴关系狼疮肾炎纵向队列中对172例患者进行时间至事件分析,中位随访4.6年,33%发生肾功能丢失。基线低eGFR、非首次肾活检及较高NIH慢性指数与eGFR丢失相关,慢性指数是最强预测因子但无明确阈值;12个月蛋白尿<0.7 g/g与较低风险相关,但无单一阈值确保保护;3、6或12个月缺乏完全临床缓解预测未来eGFR丢失,部分缓解为中等风险;血清学标志物与eGFR丢失无关。
要点
- 基线低eGFR、非首次肾活检及高NIH慢性指数预测肾功能丢失,慢性指数最强但无明确阈值。
- 12个月尿蛋白/肌酐比<0.7 g/g与较好结局相关,但无单一阈值确保保护。
- 3、6或12个月缺乏完全临床缓解预测未来eGFR丢失,部分缓解为中等风险。
核心结论
- 基线低eGFR和慢性组织学损伤而非活动性或ISN分型预测eGFR丢失。
- 1年时蛋白尿<0.7 g/g与较好结局相关但不确保保护。
- 现有缓解定义更适合作为预后指标而非真正疗效衡量,需要更好的生物标志物。
研究设计与样本
- 加速药物伙伴关系狼疮肾炎纵向队列的时间至事件分析。
- 纳入172例狼疮肾炎患者,中位随访4.6年(范围0.5-7.8年)。
主要发现
- 172例中57例(33%)发生肾功能丢失(持续≥40% eGFR下降或进展至终末期肾病)。
- 基线较低eGFR、非首次肾活检和较高NIH慢性指数与eGFR丢失相关。
- NIH活动指数和ISN分型无预测作用。
- 12个月蛋白尿有预后价值,尿蛋白/肌酐比<0.7 g/g与较低风险相关,但无单一阈值确保保护,更低水平结局更好。
- 3、6或12个月缺乏完全临床缓解预测未来eGFR丢失,部分缓解为中等风险;血清学标志物与eGFR丢失无关。
关键数值与推荐
- 肾功能丢失定义为持续≥40% eGFR下降或进展至终末期肾病。
- 12个月尿蛋白/肌酐比<0.7 g/g与较低风险相关,但无单一阈值确保保护。
- 3、6或12个月缺乏完全临床缓解预测未来eGFR丢失,部分缓解为中等风险。
临床怎么用
- 评估狼疮肾炎预后时应关注基线eGFR、肾活检慢性指数及非首次肾活检。
- 随访中12个月蛋白尿水平可用于风险分层,但不应仅凭阈值判断治疗成功。
- 现有临床缓解定义宜作为预后指标,提示需要更佳生物标志物反映肾内炎症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long-term predictors remain inadequately studied, requiring long-term follow-up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort. METHODS: We performed time-to-event analyses of clinical, centrally scored histologic, and serological predictors of kidney function loss (sustained ≥40% estimated glomerular filtration rate [eGFR] decline or progression to end-stage kidney disease) in 172 LN patients with a median follow-up of 4.6 years (range 0.5-7.8). RESULTS: Kidney function loss occurred in 57 of 172 (33%) patients. Baseline lower eGFR, non-first kidney biopsy, and higher National Institutes of Health (NIH) chronicity index were associated with eGFR loss. Chronicity index was the strongest predictor, but no clear threshold defined higher risk. NIH activity index and International Society of Nephrology (ISN) class were not predictive. Proteinuria at 12 months was prognostic, with urine protein-to-creatinine ratio <0.7 g/g associated with lower risk; however, no single threshold ensured protection, and lower levels had better outcomes. Lack of complete clinical response at 3, 6, or 12 months predicted future eGFR loss, whereas partial response conferred intermediate risk. Serological markers were not associated with eGFR loss. CONCLUSION: Low baseline eGFR and chronic histologic damage, but not activity or ISN class, predicted eGFR loss. Proteinuria <0.7 g/g at one year was associated with better outcomes but did not ensure protection. Because proteinuria does not reflect intrarenal inflammation, these results suggest current response definitions serve better as prognostic indicators than true measures of treatment efficacy, and better biomarkers are needed.
引用
- Zhang S, Magder L, Goldman D, et al. Clinical, Histologic, and Serological Predictors of Renal Function Loss in Lupus Nephritis. Arthritis Care Res (Hoboken). 2026. PMID: 42047336. doi:10.1002/acr.80070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。